CN114159479A - Probiotic powder for treating female vaginal infection and preparation method thereof - Google Patents
Probiotic powder for treating female vaginal infection and preparation method thereof Download PDFInfo
- Publication number
- CN114159479A CN114159479A CN202111497018.3A CN202111497018A CN114159479A CN 114159479 A CN114159479 A CN 114159479A CN 202111497018 A CN202111497018 A CN 202111497018A CN 114159479 A CN114159479 A CN 114159479A
- Authority
- CN
- China
- Prior art keywords
- powder
- probiotic
- aqueous solution
- probiotic powder
- carboxymethyl starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The application relates to the field of probiotic preparations, and particularly discloses a probiotic powder for treating female vaginal infection and a preparation method thereof. A probiotic powder for treating female vaginal infection comprises the following raw materials in parts by mass per 6g of probiotic powder: 0.1-2 g of prebiotics; 0.1-1 g of auxiliary materials; 1-3.8 g of composite probiotic powder; the balance is wrapping wall materials; the composite probiotic powder comprises lactobacillus crispatus powder a, lactobacillus crispatus powder b and bifidobacterium longum powder. The probiotic powder has the advantage of improving the treatment effect on vaginitis.
Description
Technical Field
The application relates to the field of probiotic preparations, in particular to a probiotic powder for treating female vaginal infection and a preparation method thereof.
Background
Vaginitis is a common disease of women, symptoms of the vaginitis comprise pruritus, burning pain, irritation, abnormal fluid and the like, the vaginitis can be developed in all age groups, and the onset of the vaginitis tends to be younger due to the fact that young people like staying up all night, sitting for a long time, lack of exercise, unhealthy diet, long-term eating of spicy, cold and greasy food and irregularity, and the treatment of the vaginitis is increasingly valued.
Generally, the medicine for treating the vaginitis is mainly used for external application, the medicine for oral administration can also be used for treating the vaginitis, the medicine mainly comprises antibiotics, metronidazole, estrogen and preparations for acidifying the vagina and is used for killing pathogenic microorganisms in the vagina, although the medicine can effectively kill pathogenic bacteria in the vagina, normal flora in the vaginal microecology can be killed, vaginal flora imbalance is caused, bacterial drug resistance is caused, even the vaginitis recurs, and the treatment effect is poor.
Disclosure of Invention
In order to improve the treatment effect on vaginitis, the application provides probiotic powder for treating female vaginal infection and a preparation method thereof.
In a first aspect, the present application provides a probiotic powder for treating vaginal infections in women, using the following technical scheme:
a probiotic powder for treating female vaginal infection comprises the following raw materials in parts by mass per 6g of probiotic powder:
0.1-2 g of prebiotics;
0.1-1 g of auxiliary materials;
1-3.8 g of composite probiotic powder;
the balance is wrapping wall materials;
the composite probiotic powder comprises lactobacillus crispatus powder a, lactobacillus crispatus powder b and bifidobacterium longum powder.
By adopting the technical scheme, compared with the treatment of vaginal infection by using antibiotics in the related technology, the treatment mode of the application maintains normal flora, and adopts the mode of compound probiotics to harmonize the flora in the vagina, namely, microorganisms are utilized to form a mutually coordinated microecosystem in the vagina, thereby maintaining the health of the vagina.
Lactobacillus crispatus is one of the main dominant lactobacilli in the vagina, and can damage the cell walls of pathogenic bacteria, inhibit the growth of pathogenic bacteria such as Gardner, Staphylococcus aureus, Escherichia coli and Candida albicans in the vagina and maintain normal vaginal flora by competing with the pathogenic bacteria for nutrient substances, secreting lactic acid, hydrogen peroxide, bacteriocin and other antibacterial substances, thereby treating vaginal infection.
The bifidobacterium longum can be adhered to epithelial cells of the vagina, occupies the living space of pathogenic bacteria, inhibits the growth of the pathogenic bacteria, maintains the weak acid environment in the vagina, and has a synergistic effect with lactobacillus crispatus, so that the antibacterial effect is better, and the balance of a vaginal microecosystem can be jointly maintained, thereby keeping the vaginal health.
Preferably, the mass ratio of the lactobacillus crispatus powder a to the lactobacillus crispatus powder b to the bifidobacterium longum powder is 1 (0.5-1) to 1.5-2.
By adopting the technical scheme, the proportion of the composite probiotics can improve the synergistic effect of the lactobacillus crispatus and the bifidobacterium longum, thereby improving the bacteriostatic effect.
Preferably, the prebiotic is selected from one or more of fructooligosaccharide, stachyose and lactitol.
By adopting the technical scheme, the fructo-oligosaccharide, the stachyose and the lactitol can provide nutrition for the composite probiotics and promote the growth of the composite probiotics, so that the quantity of the composite probiotics is increased, and the requirement of a vaginal microecosystem is met.
Preferably, the auxiliary material is selected from one or more of maltodextrin and hawthorn fruit powder.
By adopting the technical scheme, the maltodextrin and the hawthorn fruit powder can be used as carriers of the composite probiotics, so that the stability of the composite probiotics is improved, and the effectiveness of the composite probiotics is further improved.
In a second aspect, the present application provides a method for preparing probiotic powder for treating female vaginal infection, which adopts the following technical scheme:
a preparation method of probiotic powder for treating female vaginal infection comprises the following steps:
s1, placing composite probiotic powder in physiological saline, and homogenizing to obtain a thallus mixed solution;
s2, mixing the thallus mixed liquor with a wrapping wall material to obtain a probiotic micro-capsule;
and S3, uniformly mixing the probiotic microcapsules, the prebiotics and the auxiliary materials, and drying to obtain the probiotic powder.
By adopting the technical scheme, the composite probiotic powder is firstly formed into the probiotic microcapsules, the tolerance of the composite probiotic powder to the external environment is improved by utilizing a microencapsulation embedding mode, and particularly the influence of the vaginal peracid environment on the composite doctor bacterial powder during vaginal infection is reduced, so that the viable count of the composite probiotic powder during use is improved, and the antibacterial effect is improved.
Preferably, the wrapping wall material comprises xanthan gum, sodium carboxymethyl starch and soybean oil, and the step S2 specifically comprises: and mixing and stirring the thallus mixed solution and the xanthan gum aqueous solution, adding soybean oil and dropwise adding a carboxymethyl starch sodium aqueous solution, continuously stirring, and filtering to obtain the probiotic micro-capsules.
By adopting the technical scheme, the microcapsules formed by the xanthan gum, the sodium carboxymethyl starch and the soybean oil have high stability, and the speed of releasing the composite probiotics is moderate, so that the microcapsule is suitable for the vaginal environment.
Preferably, the mass ratio of the composite probiotic powder to the physiological saline is 1 (96-99), the mass fraction of the xanthan gum aqueous solution is 20-25%, the mass fraction of the carboxymethyl starch sodium aqueous solution is 10-15%, and the mass ratio of the thallus mixed solution, the xanthan gum aqueous solution, the carboxymethyl starch sodium aqueous solution and the soybean oil is 1 (2-2.5) to 1.5-2 (1-1.5).
By adopting the technical scheme, the probiotic microcapsule with higher stability can be formed according to the proportion.
Preferably, in the step S2, the carboxymethyl starch sodium aqueous solution and the soybean oil are sequentially added, the carboxymethyl starch sodium aqueous solution accounting for 50-60% of the total weight of the carboxymethyl starch sodium aqueous solution is dropwise added while stirring, then the soybean oil is added, ultrasonic vibration is performed, the remaining carboxymethyl starch sodium aqueous solution is dropwise added, then stirring and filtering are performed, and the probiotic microcapsule is obtained.
Through adopting above-mentioned technical scheme, adopt carboxymethyl starch sodium water solution-soybean oil-carboxymethyl starch sodium water solution's addition order, make the fungus powder surface wrap up by thinner wall material earlier, soybean oil ultrasonic dispersion forms the water dispersion of oil in aquatic, thereby the water dispersion of oil in oil makes the wall material thickening with thinner wall material contact, replenish carboxymethyl starch sodium water solution again at last, pack the wall material, can improve the steadiness of wall material, thereby form the microcapsule that the tolerance is good, and because the water dispersion of oil in oil forms at the intermediate process, make the wall material have sufficient space to supply the fungus powder to release, thereby control fungus powder release speed, improve antibacterial effect.
In summary, the present application has the following beneficial effects:
1. the method is characterized in that a compound probiotic formed by lactobacillus crispatus and bifidobacterium longum is adopted to harmonize flora in the vagina, namely, microorganisms are utilized to form a micro-ecological system which is mutually coordinated in the vagina, so that the vagina health is maintained.
2. In the application, the composite probiotics is preferably prepared by a microencapsulation embedding method, so that the tolerance of the composite probiotic powder to the external environment is improved, the release speed of the composite probiotics is controlled, and the antibacterial effect is improved.
Detailed Description
The present application will be described in further detail with reference to examples.
The Lactobacillus crispatus A is preserved by China general microbiological culture Collection center (CGMCC), the preservation time is 10 and 11 days in 2021, the viability detection time is 11 days in 10 and 11 months in 2021, the viability detection result is survival, the Lactobacillus crispatus (Lactobacillus crispatus) HLC28 is named, and the registration number is CGMCC No. 31312; the preservation mechanism of the Lactobacillus crispatus b is a Guangdong province microorganism strain preservation center, the preservation time is 12 and 4 days in 2019, the viability detection time is 12 and 6 days in 2019, the viability detection result is survival, the name is Lactobacillus crispatus (CCFM 1110), and the registration number is GDMCCNo: 60918;
the long Bifidobacterium preservation organization is China general microbiological culture Collection center, the preservation time is 2021 year, 9 month and 21 days, the viability detection result is survival, the name is long Bifidobacterium (Bifidobacterium longum) HBL79, and the registration number is CGMCC No. 31104;
fructo-oligosaccharide is purchased from Shenzhen Lefu Biotech limited, CAS number 57-48-7;
stachyose was purchased from Shenzhen Lefu Biotech, Inc., CAS number 10094-58-3;
lactitol was purchased from Shenzhen Lefu Biotech, Inc., CAS number 585-86-4;
maltodextrin was selected from the available from denying sincerity biotechnology limited, CAS number 9050-36-6;
the hawthorn fruit powder is selected from Xian Jinjufang plant technology development Limited company;
xanthan gum is purchased from Shenzhen Lefu Biotech Co., Ltd, CAS No. 11138-66-2;
sodium carboxymethyl starch was selected from Jiangsu Yukun Biotech Co., Ltd, CAS No. 9063-38-1;
the normal saline is sodium chloride solution with mass concentration of 0.9%.
Preparation example
Preparation example 1
Preparation of aqueous xanthan gum solution:
taking 20g of xanthan gum, dissolving the xanthan gum in 80g of water, and mixing and stirring for 3min to obtain a xanthan gum aqueous solution.
Preparation example 2
Preparation of aqueous xanthan gum solution:
taking 25g of xanthan gum, dissolving the xanthan gum in 75g of water, and mixing and stirring for 3min to obtain a xanthan gum aqueous solution.
Preparation example 3
Preparation of sodium carboxymethyl starch aqueous solution:
taking 10g of xanthan gum, dissolving the xanthan gum in 90g of water, and mixing and stirring for 3min to obtain a xanthan gum aqueous solution.
Preparation example 4
Preparation of sodium carboxymethyl starch aqueous solution:
taking 15g of xanthan gum, dissolving the xanthan gum in 85g of water, mixing and stirring for 3min to obtain a xanthan gum aqueous solution.
Examples
Example 1
Preparation of probiotic powder for the treatment of vaginal infections in women:
s1, taking composite probiotic powder, wherein the composite probiotic powder comprises 0.95g of lactobacillus crispatus powder a, 1.9g of lactobacillus crispatus powder b and 0.95g of bifidobacterium bifidum powder, and the living bacteria amount of the lactobacillus crispatus powder a is 3.0 multiplied by 109CFU/g, the viable bacteria amount of Lactobacillus crispatus powder b is 5.0 multiplied by 109CFU/g, viable count of Bifidobacterium longum powder is 3.0 × 109CFU/g, dispersing the composite probiotic powder in 96g of normal saline, and homogenizing by using a homogenizer to obtain a thallus mixed solution;
s2, mixing and stirring the thallus mixed liquor and 100g of xanthan gum aqueous solution of the preparation example 1 for 2min, dropwise adding 100g of carboxymethyl starch sodium aqueous solution of the preparation example 3 for 10min, adding 100g of soybean oil after dropwise adding, continuously stirring for 20min, and filtering to obtain probiotic microcapsules;
s3, uniformly mixing the probiotic microcapsules, 0.1g of fructo-oligosaccharide and 0.1g of maltodextrin, and drying to obtain the probiotic powder.
Example 2
Preparation of probiotic powder for the treatment of vaginal infections in women:
s1, taking composite probiotic powder, wherein the composite probiotic powder comprises 0.25g of lactobacillus crispatus powder a, 0.5g of lactobacillus crispatus powder b and 0.25g of bifidobacterium bifidum powder, and the living bacteria amount of the lactobacillus crispatus powder a is 3.0 multiplied by 109CFU/g, the viable bacteria amount of Lactobacillus crispatus powder b is 5.0 multiplied by 109CFU/g, viable count of Bifidobacterium longum powder is 3.0 × 109CFU/g, dispersing the composite probiotic powder in 99g of physiological saline, and homogenizing by using a homogenizer to obtain a thallus mixed solution;
s2, mixing and stirring the thallus mixed liquor and 100g of xanthan gum aqueous solution of the preparation example 2 for 2min, dropwise adding 100g of carboxymethyl starch sodium aqueous solution of the preparation example 4 for 10min, adding 100g of soybean oil after dropwise adding, continuously stirring for 20min, and filtering to obtain probiotic microcapsules;
s3, uniformly mixing the probiotic microcapsules, 2g of fructo-oligosaccharide and 1g of maltodextrin, and drying to obtain the probiotic powder.
Example 3
Preparation of probiotic powder for the treatment of vaginal infections in women:
s1, taking composite probiotic powder, wherein the composite probiotic powder comprises 0.7g of lactobacillus crispatus powder a, 1.4g of lactobacillus crispatus powder b and 0.7g of bifidobacterium bifidum powder, and the living bacteria amount of the lactobacillus crispatus powder a is 3.0 multiplied by 109CFU/g, the viable bacteria amount of Lactobacillus crispatus powder b is 5.0 multiplied by 109CFU/g, viable count of Bifidobacterium longum powder is 3.0 × 109CFU/g, dispersing the composite probiotic powder in 97g of normal saline, and homogenizing by using a homogenizer to obtain a thallus mixed solution;
s2, mixing and stirring the thallus mixed liquor and 100g of xanthan gum aqueous solution of the preparation example 2 for 2min, dropwise adding 100g of carboxymethyl starch sodium aqueous solution of the preparation example 4 for 10min, adding 100g of soybean oil after dropwise adding, continuously stirring for 20min, and filtering to obtain probiotic microcapsules;
s3, uniformly mixing the probiotic microcapsules, 0.2g of fructo-oligosaccharide, 0.2g of stachyose, 0.4g of maltodextrin and 0.4g of hawthorn fruit powder, and drying to obtain probiotic powder.
Example 4
Preparation of probiotic powder for the treatment of vaginal infections in women:
s1, taking composite probiotic powder, wherein the composite probiotic powder comprises 0.5g of lactobacillus crispatus powder a, 1g of lactobacillus crispatus powder b and 0.5g of bifidobacterium longum powder, and the living bacteria amount of the lactobacillus crispatus powder a is 3.0 multiplied by 109CFU/g, the viable bacteria amount of Lactobacillus crispatus powder b is 5.0 multiplied by 109CFU/g, viable count of Bifidobacterium longum powder is 3.0 × 109CFU/g, dispersing the composite probiotic powder in 98g of physiological saline, and homogenizing by using a homogenizer to obtain a thallus mixed solution;
s2, mixing and stirring the thallus mixed liquor and 100g of xanthan gum aqueous solution of the preparation example 2 for 2min, dropwise adding 100g of carboxymethyl starch sodium aqueous solution of the preparation example 4 for 10min, adding 100g of soybean oil after dropwise adding, continuously stirring for 20min, and filtering to obtain probiotic microcapsules;
s3, uniformly mixing the probiotic microcapsules, 0.3g of fructo-oligosaccharide, 0.2g of stachyose, 0.2g of lactitol, 0.8g of maltodextrin and 0.5g of hawthorn fruit powder, and drying to obtain probiotic powder.
Example 5
Preparation of probiotic powder for the treatment of vaginal infections in women:
this example is different from example 4 in that lactobacillus crispatus powder a was added in an amount of 0.67g, lactobacillus crispatus powder b was added in an amount of 0.33g, and bifidobacterium longum powder was added in an amount of 1g in step S1.
Example 6
Preparation of probiotic powder for the treatment of vaginal infections in women:
this example is different from example 4 in that lactobacillus crispatus powder a was added in an amount of 0.5g, lactobacillus crispatus powder b was added in an amount of 0.5g, and bifidobacterium longum powder was added in an amount of 1g in step S1.
Example 7
Preparation of probiotic powder for the treatment of vaginal infections in women:
this example is different from example 6 in that, in the step of S2, the amount of xanthan gum aqueous solution added was 200g, the amount of carboxymethyl starch sodium aqueous solution added was 150g, and the amount of soybean oil added was 100 g.
Example 8
Preparation of probiotic powder for the treatment of vaginal infections in women:
this example is different from example 6 in that, in the step of S2, the amount of xanthan gum aqueous solution added was 250g, the amount of carboxymethyl starch sodium aqueous solution added was 200g, and the amount of soybean oil added was 150 g.
Example 9
Preparation of probiotic powder for the treatment of vaginal infections in women:
the present embodiment is different from embodiment 8 in that the step S2 is: and mixing and stirring the thallus mixed liquor and 200g of xanthan gum aqueous solution of preparation example 2 for 2min, dropwise adding 100g of carboxymethyl starch sodium aqueous solution of preparation example 4 for 10min, adding 150g of soybean oil after dropwise adding, ultrasonically vibrating for 20min, dropwise adding the rest 100g of carboxymethyl starch sodium aqueous solution of preparation example 4 for 10min, continuously stirring for 20min, and filtering to obtain the probiotic microcapsule.
Comparative example
Comparative example 1
This comparative example differs from example 4 in that in this comparative example, the same amount of fructooligosaccharide was used instead of lactobacillus crispatus powder a.
Comparative example 2
This comparative example differs from example 4 in that in this comparative example, the same amount of fructooligosaccharide was used instead of lactobacillus crispatus powder b.
Comparative example 3
This comparative example differs from example 4 in that in this comparative example, the bifidobacterium longum powder was replaced by an equal amount of fructo-oligosaccharide.
Comparative example 4
This comparative example differs from example 4 in that in this comparative example, the steps S1 and S2 are not provided, i.e. the steps of preparing a probiotic powder for the treatment of vaginal infections in women are:
uniformly mixing 0.5g of lactobacillus crispatus powder a, 1g of lactobacillus crispatus powder b, 0.5g of bifidobacterium longum, 0.3g of fructo-oligosaccharide, 0.2g of stachyose, 0.2g of lactitol, 0.8g of maltodextrin and 0.5g of hawthorn fruit powder to obtain the probiotic powder.
Performance test
The probiotic powder prepared in the examples 1-9 and the comparative examples 1-4 of the application is used for in vitro bacteriostasis test, and the bacteriostasis capability of the probiotic powder to pathogenic bacteria is tested, wherein the pathogenic bacteria are selected from gardnerella, staphylococcus aureus, escherichia coli and candida albicans and are respectively tested.
Taking a culture medium, adjusting the pH of the culture medium to 2.8, uniformly coating a culture solution of pathogenic bacteria in the culture medium, and putting the culture medium into an oxford cup after the culture medium is completely absorbed; taking 0.1g of probiotic powder, dissolving in 5mL of physiological saline to prepare probiotic bacteria liquid, adding 100 mu L of probiotic bacteria liquid into an Oxford cup, absorbing for 4h at 4 ℃, then culturing for 24h in a constant-temperature incubator at 37 ℃, finally taking out and determining the diameter of a bacteriostatic zone, wherein the larger the diameter of the bacteriostatic zone is, the higher the bacteriostatic ability of the probiotic powder is, and the test result is shown in Table 1.
TABLE 1
As can be seen from table 1, comparing example 4 with comparative examples 1-3, when the composite probiotic powder of the present application is used, i.e., when lactobacillus crispatus powder a, lactobacillus crispatus powder b and bifidobacterium longum powder are added simultaneously, the bacteriostatic effect on bacteria which are easily causing vaginal infection diseases, such as gardner bacteria, staphylococcus aureus, escherichia coli and candida albicans, is the best, and the synergistic effect among lactobacillus crispatus powder a, lactobacillus crispatus powder b and bifidobacterium longum powder is demonstrated to produce a good bacteriostatic effect.
Compared with the comparative example 4, the preparation method of the probiotic powder by the microencapsulation embedding method can improve the acid resistance of the probiotic powder, so that the lactobacillus crispatus, the lactobacillus crispatus and the bifidobacterium longum can be better released, and the bacteriostatic effect is improved.
The examples 1 to 4 all have good bacteriostatic effects, and compared with the example 4, the examples 5 to 6 have larger bacteriostatic circle diameters, which shows that when the mass ratio of the lactobacillus crispatus powder a to the lactobacillus crispatus powder b to the bifidobacterium longum powder is adjusted to be within the range of 1 (0.5-1) to 1.5-2, the three probiotics can exert better bacteriostatic effects.
Comparing examples 7-8 with example 6, the diameter of the zone of inhibition is larger, which shows that the inhibition effect is improved by controlling the proportion of the wrapping wall material, i.e. controlling the mass ratio of the thallus mixed solution, the xanthan gum aqueous solution, the carboxymethyl starch sodium aqueous solution and the soybean oil to be in the range of 1 (2-2.5) to (1.5-2) to (1-1.5).
Comparing example 9 with example 8, the diameter of the inhibition zone is larger, which shows that the inhibition effect can be improved by adding carboxymethyl starch sodium aqueous solution-soybean oil-carboxymethyl starch sodium aqueous solution in sequence.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (8)
1. The probiotic powder for treating female vaginal infection is characterized in that each 6g of probiotic powder contains the following raw materials in parts by mass:
0.1-2 g of prebiotics;
0.1-1 g of auxiliary materials;
1-3.8 g of composite probiotic powder;
the balance is wrapping wall materials;
the composite probiotic powder comprises lactobacillus crispatus powder a, lactobacillus crispatus powder b and bifidobacterium longum powder.
2. A probiotic powder for use in the treatment of vaginal infections in women, according to claim 1, characterized in that: the mass ratio of the lactobacillus crispatus powder a to the lactobacillus crispatus powder b to the bifidobacterium longum powder is 1 (0.5-1) to 1.5-2.
3. A probiotic powder for use in the treatment of vaginal infections in women, according to claim 1, characterized in that: the prebiotics are selected from one or more of fructo-oligosaccharide, stachyose and lactitol.
4. A probiotic powder for use in the treatment of vaginal infections in women, according to claim 1, characterized in that: the auxiliary material is selected from one or more of maltodextrin and hawthorn fruit powder.
5. A method for preparing a probiotic powder for the treatment of vaginal infections in women, for the preparation of a probiotic powder for the treatment of vaginal infections in women according to any of claims 1 to 4, comprising the steps of:
s1, placing composite probiotic powder in physiological saline, and homogenizing to obtain a thallus mixed solution;
s2, mixing the thallus mixed liquor with a wrapping wall material to obtain a probiotic micro-capsule;
and S3, uniformly mixing the probiotic microcapsules, the prebiotics and the auxiliary materials, and drying to obtain the probiotic powder.
6. A method of preparing a probiotic powder for the treatment of vaginal infections in women, according to claim 5, characterized in that: the wrapping wall material comprises xanthan gum, sodium carboxymethyl starch and soybean oil, and the S2 step specifically comprises the following steps: and mixing and stirring the thallus mixed solution and the xanthan gum aqueous solution, adding soybean oil and dropwise adding a carboxymethyl starch sodium aqueous solution, continuously stirring, and filtering to obtain the probiotic micro-capsules.
7. A method of preparing a probiotic powder for the treatment of vaginal infections in women, according to claim 6, characterized in that: the mass ratio of the composite probiotic powder to the physiological saline is 1 (96-99), the mass fraction of the xanthan gum aqueous solution is 20-25%, the mass fraction of the carboxymethyl starch sodium aqueous solution is 10-15%, and the mass ratio of the thallus mixed solution, the xanthan gum aqueous solution, the carboxymethyl starch sodium aqueous solution and the soybean oil is 1 (2-2.5) to 1.5-2 to 1-1.5.
8. A method of preparing a probiotic powder for the treatment of vaginal infections in women, according to claim 6, characterized in that: in the step S2, sequentially adding the sodium carboxymethyl starch aqueous solution and the soybean oil, dropwise adding the sodium carboxymethyl starch aqueous solution accounting for 50-60% of the total weight of the sodium carboxymethyl starch aqueous solution while stirring, then adding the soybean oil, ultrasonically vibrating, dropwise adding the rest sodium carboxymethyl starch aqueous solution, stirring, and filtering to obtain the probiotic microcapsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111497018.3A CN114159479A (en) | 2021-12-08 | 2021-12-08 | Probiotic powder for treating female vaginal infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111497018.3A CN114159479A (en) | 2021-12-08 | 2021-12-08 | Probiotic powder for treating female vaginal infection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114159479A true CN114159479A (en) | 2022-03-11 |
Family
ID=80484718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111497018.3A Pending CN114159479A (en) | 2021-12-08 | 2021-12-08 | Probiotic powder for treating female vaginal infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114159479A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104434999A (en) * | 2014-11-07 | 2015-03-25 | 南昌大学 | Preparation method of probiotic suppository and capsules for treating female inflammation |
| CN106879507A (en) * | 2017-02-14 | 2017-06-23 | 黄怀勇 | A kind of cultural method of selenium-rich silver carp |
| CN108902983A (en) * | 2018-06-29 | 2018-11-30 | 深圳职业技术学院 | Double emulsion-spray drying production compound probiotic bilayered microcapsule technical method |
| FR3066886A1 (en) * | 2017-06-02 | 2018-12-07 | Friulchem | SOLID CURING COMPOSITIONS FOR ORAL ADMINISTRATION |
| CN111035013A (en) * | 2019-11-30 | 2020-04-21 | 江苏艾兰得营养品有限公司 | Probiotic microcapsule and preparation method thereof |
| CN111134331A (en) * | 2018-11-06 | 2020-05-12 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic microcapsule and preparation method thereof |
-
2021
- 2021-12-08 CN CN202111497018.3A patent/CN114159479A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104434999A (en) * | 2014-11-07 | 2015-03-25 | 南昌大学 | Preparation method of probiotic suppository and capsules for treating female inflammation |
| CN106879507A (en) * | 2017-02-14 | 2017-06-23 | 黄怀勇 | A kind of cultural method of selenium-rich silver carp |
| FR3066886A1 (en) * | 2017-06-02 | 2018-12-07 | Friulchem | SOLID CURING COMPOSITIONS FOR ORAL ADMINISTRATION |
| CN108902983A (en) * | 2018-06-29 | 2018-11-30 | 深圳职业技术学院 | Double emulsion-spray drying production compound probiotic bilayered microcapsule technical method |
| CN111134331A (en) * | 2018-11-06 | 2020-05-12 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic microcapsule and preparation method thereof |
| CN111035013A (en) * | 2019-11-30 | 2020-04-21 | 江苏艾兰得营养品有限公司 | Probiotic microcapsule and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| STEPHANIE S. PINTO 等: ""Potential use of whey concentrate and prebiotics as carrier agents to protect Bifidobacterium-BB-12 microencapsulated by spray drying"", 《FOOD RESEARCH INTERNATIONAL》, vol. 67, pages 400 - 408 * |
| 王野: ""双歧杆菌微胶囊化及其应用研究"", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》, no. 12, pages 024 - 37 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006257751B2 (en) | Probiotic health and performance promoting food, feed and/or drinking water additive and its use | |
| CN113736699B (en) | Enterococcus faecium microbial inoculum and application thereof | |
| CN101822321B (en) | Application of Bacillus subtilis ANSB060 | |
| CA2538676A1 (en) | Probiotic storage and delivery | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN104855684B (en) | A kind of antibacterial Chinese medicine microbial fermentation preparation and its preparation method and application | |
| CN107354097B (en) | Lactobacillus preservative for improving survival rate of liquid lactobacillus at normal temperature and application thereof | |
| CN103409334B (en) | Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen | |
| CN101199558A (en) | Compound probiotics for poultry and preparing method thereof | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN114504109B (en) | Composition containing bifidobacterium lactis and breast milk oligosaccharide and application thereof | |
| KR101000364B1 (en) | Double-coating methods for enhancing viability | |
| CN106860451A (en) | A kind of new opplication of rifamycin nitroimidazole coupling molecule | |
| EP3651783A1 (en) | New probiotic composition for prevention of bacterial vaginosis | |
| WO2016198528A1 (en) | Dietary supplement | |
| CN102907585B (en) | A kind of middle pig probiotic vitamin premix and batch | |
| WO2022001673A1 (en) | Novel use of n-acetyl-d-glucosamine and related product | |
| CN106138111A (en) | A kind of compositions for improving vaginal health | |
| CN113546096A (en) | Active probiotic formula for treating constipation and diarrhea | |
| US20210015879A1 (en) | Method for preserving probiotic composition and use thereof | |
| CN107752015A (en) | The composite nutrient food that a kind of all-digestive tract improves | |
| CN114159479A (en) | Probiotic powder for treating female vaginal infection and preparation method thereof | |
| CN114747769B (en) | Probiotic product and preparation method thereof | |
| JP2021521249A (en) | Moisture resistant probiotic granules and their manufacturing method | |
| CN114223728B (en) | Premature/low birth weight infant formula containing prebiotics and probiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |